在因心力衰竭住院治疗的老年人中,处方跌倒风险增加药物的模式
Esther Liu1, Musarrat Nahid1, Mahad Musse1
1Department of Medicine, Weill Cornell Medicine, Weill Medical College of Cornell University, 525 East 68Th Street, New York, NY, 10021, USA.
BMC cardiovascular disorders
|July 26, 2023
概括
几乎所有老年心力衰竭患者都服用降低风险增加药物 (FRID),超过一半的患者在出院时承受高负担. 这凸显了管理FRID的关键需求,以防止这一脆弱群体的下降.
科学领域:
- 老年学是一门学科.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于心力衰竭 (HF) 住院的老年人在出院后面临着严重的跌倒风险.
- 跌倒风险增加药物 (FRID) 是导致这些跌倒的可修改因素.
- 在患有HF的住院老年人中使用FRID的患病率和预测因素尚不清楚.
研究的目的:
- 为了确定FRID在老年人中患HF住院的患病率.
- 描述心血管 (CV) 和非心血管 (非CV) FRID在入院和出院时的使用模式.
- 为了确定在放电时高FRID负荷的预测因素.
主要方法:
- 利用了来自国家中风地理和种族差异原因研究 (REGARDS) 的数据.
- 包括65岁以上的参与者,在HF住院后 (2003-2017) 活着出院.
- 通过图表抽象评估FRID并使用多变量波桑回归分析高FRID负担的预测因素.
主要成果:
- 99%的患有高血压的老年人在出院时至少接受了一次FRID; 54%的FRID负担很高 (AHRQ分数≥6).
- 抗高血压药物是最常见的心血管FRID;循环利尿剂显示出患病率增幅最大.
- 高血压,情绪障碍和多药性强度与出院时的高FRID负担密切相关.
结论:
- 对于因HF住院的老年人来说,FRID的使用几乎是普遍的,很大一部分人经历了高负担.
- 管理FRID至关重要,以减轻这一群体的跌倒风险.
- 需要进一步的研究,以平衡HF治疗指南与防摔策略.
更多相关视频
07:21Walk with Me Hybrid Virtual/In-Person Walking for Older Adults with Neurodegenerative Disease
Published on: June 16, 2023
975
04:13Using a Real-Time Locating System to Measure Walking Activity Associated with Wandering Behaviors Among Institutionalized Older Adults
Published on: February 8, 2019
6.8K
相关概念视频
01:22Heart Failure Drugs: β-Blockers
364
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
364
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
01:30Heart Failure V: Medical Management
14
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
14
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:30Heart Failure VII: Nursing Interventions
97
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
97
01:26Heart Failure Drugs: Inotropic Agents
626
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
626